ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

guselkumab

Also written as “Guselkumab”, “Guselkumab Dose 1” and “Guselkumab Dose 2”.

Its studies are mostly in Psoriasis · Crohn Disease · Arthritis, Psoriatic · Colitis, Ulcerative · Arthritis, Juvenile, led by 3 companies.

Drug pageGuselkumab: every studyAll 80 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jun 3, 202160 company-led studies, 19 open or runningNext primary completion: Nov 20, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson5818 open or runningphase 4since Jun 3, 2021Sep 2, 2011Feb 10, 2027phase 3 · NCT06260163
Eli Lillyits history only10 open or runningphase 4since Jun 20, 2018Jun 20, 2018none ahead
Surmount Servicesits history only11 open or runningphase 1since Aug 20, 2026Aug 20, 2026Nov 20, 2026phase 1 · NCT07788807

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Johnson & Johnson only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 43 studies since Sep 2, 2011.

  1. Feb 15, 20222 phase 2 studiesNCT05242484, NCT05242471
  2. Mar 1, 2022Phase 3 study in Plaque PsoriasisNCT05272150 · 211 enrolled · United States, Canada
  3. Apr 21, 2022Phase 3 study in Fistulizing Crohns DiseaseNCT05347095 · 288 enrolled · United States, Australia, Belgium and more
  4. Aug 19, 2022Phase 3 study in Colitis, UlcerativeNCT05528510 · 418 enrolled · United States, Argentina, Australia and more
  5. Mar 13, 2023Phase 3 study in Crohn DiseaseNCT05784129 · 4 enrolled · United States, Poland
  6. Jun 20, 2023Phase 3 study in Crohn DiseaseNCT05923073 · 120 planned · United States, Australia, Austria and more
  7. Sep 9, 2023Phase 3 study in Moderate Plaque PsoriasisNCT06039189 · 338 enrolled · United States, Canada
  8. Feb 7, 2024Phase 3 study in Colitis, UlcerativeNCT06260163 · 112 enrolled · United States, Australia, Belgium and more
  9. May 7, 2024Phase 3 study in Crohn DiseaseNCT06408935 · 120 enrolled · United States, Australia, Belgium and more
  10. Oct 28, 2024Phase 3 study in Crohn DiseaseNCT06663332 · 196 planned · United States, Argentina, Australia and more
  11. Aug 21, 2025Phase 4 study in Arthritis, PsoriaticNCT07141004 · 100 planned · India
  12. Dec 16, 2025Phase 4 study in Crohn DiseaseNCT07310095 · 78 planned · China
  13. Mar 23, 2026Phase 3 study in Crohn DiseaseNCT07499232 · 530 planned · United States, Austria, Belgium and more
  14. Jun 12, 2026Phase 4 study in PsoriasisNCT07654751 · 10 planned · United States

Ahead

  1. Feb 10, 2027Primary completion: phase 3 study in Colitis, UlcerativeNCT06260163
  2. Mar 25, 2027Primary completion: phase 3 study in Fistulizing Crohns DiseaseNCT05347095
  3. Apr 1, 2027Primary completion: phase 4 study in Arthritis, PsoriaticNCT04929210
  4. Jun 5, 2027Primary completion: phase 4 study in Arthritis, PsoriaticNCT07141004

TargetBeta

IL12B →IL23A →read by rule
“Interleukin-23 inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
risankizumabruleAbbViephase 468
mirikizumabruleEli Lillyphase 436

Studies

All 58 Johnson & Johnson leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07654751Psoriasis · United States4RecruitingAug 31, 202710
NCT07499232Crohn Disease · United States, Austria, Belgium and more3RecruitingNov 15, 2028530
NCT07310095Crohn Disease · China4RecruitingSep 15, 202778
NCT07141004Arthritis, Psoriatic · India4RecruitingJun 5, 2027100
NCT06663332Crohn Disease · United States, Argentina, Australia and more3RecruitingDec 12, 2031196
NCT06408935Crohn Disease · United States, Australia, Belgium and more3Active, not recruitingJun 8, 2027120
NCT06260163Colitis, Ulcerative · United States, Australia, Belgium and more3Active, not recruitingFeb 10, 2027112
NCT06039189Moderate Plaque Psoriasis · United States, Canada3CompletedApr 14, 2025338
NCT05923073Crohn Disease · United States, Australia, Austria and more3RecruitingOct 27, 2027120
NCT05784129Crohn Disease · United States, Poland3TerminatedSep 29, 20234
NCT05528510Colitis, Ulcerative · United States, Argentina, Australia and more3Active, not recruitingApr 2, 2024418
NCT05347095Fistulizing Crohns Disease · United States, Australia, Belgium and more3Active, not recruitingMar 25, 2027288
NCT05272150Plaque Psoriasis · United States, Canada3CompletedMay 30, 2025211
NCT05242484Colitis, Ulcerative · United States, Argentina, Australia and more2Active, not recruitingMay 15, 2025577
NCT05242471Crohn Disease · United States, Australia, Austria and more2Active, not recruitingMay 23, 2025703
NCT05197049Crohn Disease · United States, Australia, Belgium and more3Active, not recruitingJul 4, 2023350
NCT05125679Psoriasis · Germany, Greece, Italy4TerminatedJul 28, 202315
NCT05083078Arthritis, Psoriatic · Austria1TerminatedJul 1, 202211
NCT05083182Arthritis, Juvenile · United States, Argentina, Denmark and more3CompletedJan 12, 202648
NCT04936308Arthritis, Psoriatic · United States, Argentina, Australia and more3CompletedOct 28, 2024453
NCT04929210Arthritis, Psoriatic · United States, Argentina, Australia and more4Active, not recruitingApr 1, 2027411
NCT04914429Psoriasis · China4CompletedSep 26, 2023327
NCT04882098Arthritis, Psoriatic · United States, Australia, Bosnia and Herzegovina and more3Active, not recruitingDec 30, 20241,054
NCT04704843Celiac Disease · United States1WithdrawnSep 13, 20210
NCT04683029Scleroderma, Systemic · Japan2CompletedMay 17, 202356
NCT04633447Giant Cell Arteritis · United States, Belgium, Canada and more2TerminatedMay 22, 202453
NCT04617691Healthy · Germany1CompletedJul 20, 2021140
NCT04397263Crohn Disease · Japan3CompletedFeb 29, 202438
NCT04376827Lupus Nephritis · United States, Argentina, Mexico and more2TerminatedFeb 1, 202333
NCT04147338Healthy · United States, Germany1CompletedSep 13, 2021440
NCT04033445Colitis, Ulcerative · United States, Argentina, Australia and more3Active, not recruitingSep 19, 20231,064
NCT04030533Healthy · China1CompletedDec 31, 202060
NCT03998683Psoriasis · France, Germany, Italy and more3CompletedMar 2, 2021117
NCT03818035Psoriasis · France, Germany3CompletedMar 7, 2022880
NCT03796858Arthritis, Psoriatic · Belgium, Bulgaria, France and more3CompletedNov 11, 2020285
NCT03662542Colitis, Ulcerative · United States, Argentina, Australia and more2CompletedDec 1, 2020214
NCT03649971Adenomatous Polyposis Coli · United States, France, Germany and more1CompletedSep 13, 202177
NCT03628924Hidradenitis Suppurativa · United States, Canada, Denmark and more2CompletedMay 22, 2020184
NCT03536325Healthy · Japan1CompletedOct 25, 201824
NCT03466411Crohn Disease · United States, Australia, Austria and more3Active, not recruitingOct 20, 20231,409
NCT03451851Psoriasis · United States, Australia, Belgium and more3Active, not recruitingJul 19, 2023120
NCT03162796Arthritis, Psoriatic · United States, Australia, Canada and more3CompletedMar 14, 2019383
NCT03158285Arthritis, Psoriatic · United States, Bulgaria, Czechia and more3CompletedFeb 25, 2019741
NCT03090100Psoriasis · United States, Australia, Canada and more3CompletedAug 2, 20181,048
NCT02951533Psoriasis · Germany3CompletedSep 13, 2017119
NCT02905331Psoriasis · United States, Canada, Poland3CompletedFeb 6, 201878
NCT02641730Psoriasis · Japan3CompletedMar 28, 2017159
NCT02570373Healthy · United States1CompletedJan 12, 20168
NCT02397382Psoriasis · United States1CompletedAug 31, 201616
NCT02343744Psoriasis · Japan3CompletedDec 4, 201521
NCT02325219Psoriasis · Japan3CompletedMar 2, 2016192
NCT02319759Arthritis, Psoriatic · United States, Canada, Germany and more2CompletedMay 31, 2016149
NCT02203032Psoriasis · United States, Australia, Canada and more3CompletedDec 25, 2015872
NCT01866007Healthy · United States1CompletedSep 20, 2013141
NCT01845987Psoriasis · Japan2CompletedSep 201449
NCT01645280Arthritis, Rheumatoid · United States, Argentina, Bulgaria and more2CompletedDec 2013274
NCT01483599Psoriasis · United States, Belgium, Canada and more2CompletedNov 27, 2012293
NCT01484587Psoriasis · Japan1CompletedApr 11, 201324

How it is read

Names in the registry

  • “Guselkumab”, 43 entries
  • “Guselkumab Dose 1”, 7 entries
  • “Guselkumab Dose 2”, 7 entries
  • “Guselkumab Dose 3”, 4 entries
  • “Guselkumab 100 mg”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.